Stocks · News reference
Standard Nuclear Q2 EPS $(0.12) Misses $(0.02) Estimate, Sales $4.736M Beat $4.298M Estimate
Standard Nuclear (NYSE:STDN) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.02) by 500 percent. This is a 100 percent decrease over losses of $(0.06) per share from the
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
UBS Maintains Buy on Standard Nuclear, Raises Price Target to $20
Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday
U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday. Shares of Ascendis Pharma A/S (NASDAQ:ASND) rose sharply on Monday. On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
RBC Capital Maintains Outperform on Standard Nuclear, Raises Price Target to $13
RBC Capital analyst Christopher Dendrinos maintains Standard Nuclear (NYSE:STDN) with a Outperform and raises the price target from $11 to $13.